DATA GRAPHICS | Data Byte
Eight PDUFA dates on deck in April
J&J and Legend’s CAR T therapy could move into earlier lines; Day One could get its first marketed product
March 28, 2024 11:51 PM UTC
The eight disclosed PDUFA dates on FDA’s April calendar include an application to move BCMA-targeted CAR T cell therapy Carvykti into earlier-line treatment of multiple myeloma.
FDA has set a target action date of April 5 on an sBLA seeking approval of Carvykti ciltacabtagene autoleucel from Johnson & Johnson (NYSE:JNJ) and Legend Biotech Corp. (NASDAQ:LEGN) for second-line treatment of multiple myeloma...
BCIQ Company Profiles